Related references
Note: Only part of the references are listed.ESC 2022 guidelines on cardio-oncology in collaboration with the European Hematology Association (EHA), European Society of Therapeutic Radiology and Oncology (ESTRO) and International Cardio-Oncology Society (IC- OS) developed by the Cardio-Oncology Task Force of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
GIORNALE ITALIANO DI CARDIOLOGIA (2023)
Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses
J. Zhou et al.
CLINICAL ONCOLOGY (2022)
Atherosclerotic Progression Is Related to Immune-Related Adverse Events
Atsumasa Kurozumi et al.
INTERNATIONAL HEART JOURNAL (2022)
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
EUROPEAN HEART JOURNAL (2022)
ICIs-Related Cardiotoxicity in Different Types of Cancer
Mei Dong et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2022)
CD8+ T Cells in Atherosclerosis
Sarah Schaefer et al.
CELLS (2021)
Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors
Ming Yuan et al.
FRONTIERS IN PHARMACOLOGY (2021)
Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis
Nan Zhang et al.
EUROPEAN HEART JOURNAL (2021)
Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice
Hendrika W. Grievink et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz et al.
CANCER AND METASTASIS REVIEWS (2021)
Early Onset Acute Coronary Artery Occlusion After Pembrolizumab in Advanced Non-Small Cell Lung Cancer: A Case Report
Yuan Cheng et al.
CARDIOVASCULAR TOXICOLOGY (2021)
PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression
Yamin Liang et al.
CLINICA CHIMICA ACTA (2021)
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis
Nestor Rubio-Infante et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect
Tian Gao et al.
JOURNAL OF MATERIALS CHEMISTRY B (2021)
A snapshot of the PD-1/PD-L1 pathway
Chinmoy Ghosh et al.
JOURNAL OF CANCER (2021)
Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event
Jennifer Cautela et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
AORTIC PLAQUE PROGRESSION IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Lili Zhang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Youhai Jiang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Endogenous ApoA-I expression in macrophages: A potential target for protection against atherosclerosis
Wujun Chen et al.
CLINICA CHIMICA ACTA (2020)
PD-1/PD-L1 in cardiovascular disease
YunFeng Sun et al.
CLINICA CHIMICA ACTA (2020)
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Zsofia D. Drobni et al.
CIRCULATION (2020)
Complexity of TNF-α Signaling in Heart Disease
Filip Rolski et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Regulatory T Cell Stability and Plasticity in Atherosclerosis
Aural J. Ali et al.
CELLS (2020)
The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products
Christian Bailly
JAPANESE DENTAL SCIENCE REVIEW (2020)
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance
Priya Veluswamy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
Jiqiao Yang et al.
FRONTIERS IN PHARMACOLOGY (2019)
Macrophages and T cells in atherosclerosis: a translational perspective
Benjamin Bartlett et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
CARDIOVASCULAR ONCOLOGY: EXPLORING THE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS ON EXPERIMENTAL ATHEROSCLEROSIS
K. Poels et al.
ATHEROSCLEROSIS (2019)
Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis
Justine L. Newman et al.
CARDIOVASCULAR PATHOLOGY (2019)
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
Jair Bar et al.
EUROPEAN JOURNAL OF CANCER (2019)
Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor
Jennifer M. Kwan et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
Response by Zhou et al to Letter Regarding Article, Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure
Ling Zhou et al.
CIRCULATION (2019)
Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries
Marion Ferreira et al.
TARGETED ONCOLOGY (2018)
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
Maarten Versteven et al.
Oncotarget (2018)
Regulatory mechanisms of PD-L1 expression in cancer cells
Yongyu Shi
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?
F. Gelsomino et al.
ANNALS OF ONCOLOGY (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PD-1 checkpoint inhibition: Toxicities and management
Andrew W. Hahn et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis
Yang-Bo Hu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody
Y. Tomita et al.
ANNALS OF ONCOLOGY (2017)
Expression of coinhibitory PD-L1 on CD4+CD25+FOXP3+ regulatory T cells is elevated in patients with acute coronary syndrome
Si-Hui Li et al.
CORONARY ARTERY DISEASE (2015)
Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice
Clement Cochain et al.
PLOS ONE (2014)
Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
De-xiu Bu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis
Jun Lee et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice
Israel Gotsman et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Share Paper
